GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Orthofix Medical Inc (NAS:OFIX) » Definitions » EBIT

OFIX (Orthofix Medical) EBIT : $-111.3 Mil (TTM As of Mar. 2025)


View and export this data going back to 1992. Start your Free Trial

What is Orthofix Medical EBIT?

Orthofix Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2025 was $-47.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was $-111.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Orthofix Medical's annualized ROC % for the quarter that ended in Mar. 2025 was -29.36%. Orthofix Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -57.17%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Orthofix Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -19.92%.


Orthofix Medical EBIT Historical Data

The historical data trend for Orthofix Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthofix Medical EBIT Chart

Orthofix Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.12 -11.66 -16.42 -140.05 -94.24

Orthofix Medical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.61 -27.42 -21.43 -14.79 -47.63

Competitive Comparison of Orthofix Medical's EBIT

For the Medical Devices subindustry, Orthofix Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orthofix Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Orthofix Medical's EV-to-EBIT falls into.


;
;

Orthofix Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-111.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orthofix Medical  (NAS:OFIX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Orthofix Medical's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=-197.932 * ( 1 - -1.84% )/( (653.306 + 720.015)/ 2 )
=-201.5739488/686.6605
=-29.36 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=893.294 - 156.75 - ( 83.238 - max(0, 168.628 - 433.285+83.238))
=653.306

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Orthofix Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-190.508/( ( (139.804 + max(186.197, 0)) + (147.288 + max(193.213, 0)) )/ 2 )
=-190.508/( ( 326.001 + 340.501 )/ 2 )
=-190.508/333.251
=-57.17 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(134.713 + 189.452 + 25.882) - (156.75 + 0 + 7.1)
=186.197

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(131.865 + 174.48 + 26.012) - (45.176 + 0 + 93.968)
=193.213

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Orthofix Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2025 )
=-111.26/558.547
=-19.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orthofix Medical EBIT Related Terms

Thank you for viewing the detailed overview of Orthofix Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Orthofix Medical Business Description

Traded in Other Exchanges
Address
3451 Plano Parkway, Lewisville, TX, USA, 75056
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Executives
Geoffrey C Gillespie officer: VP, Controller, Interim CFO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Puja Leekha officer: CECO & Interim CLO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kevin J. Kenny officer: President of Global Spine C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John J. Bostjancic officer: CFO C/O SEASPINE HOLDINGS CORPORATION, 2302 LA MIRADA DRIVE, VISTA CA 92081
Keith Valentine director, officer: President & CEO 7475 LUSK BLVD., SAN DIEGO CA 92121
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Patrick L Keran officer: Chief Legal Officer 6725 MESA RIDGE RD., SUITE 100, SAN DIEGO CA 92121
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael E Paolucci director 7475 LUSK BLVD., SAN DIEGO CA 92121
Catherine M Burzik director
Rice Doug officer: CFO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kimberley A. Elting officer: Chief Legal Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056